IntoCell, Inc. (KOSDAQ:287840)

Revenue by Product

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2021
Antibody-drug Conjugate	2.91B	Log In	Log In
Antibody-drug Conjugate Growth	79.72%	Log In	Log In

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2021
South Korea	2.88B	Log In	Log In
United States	13.04M	Log In	Log In
United States Growth	119.53%	Log In	Log In
China	12.22M	Log In	Log In
China Growth	-84.08%	Log In	Log In
Europe	-	Log In	Log In